Sunday, April 20, 2014

In conversation with Elias Vamvakas

In conversation with Elias Vamvakas

January 28, 2014 by · Leave a Comment 

Tweet As CEO of San Diego-based TearLab (NASDAQ:TEAR; TSX:TLB), eye care entrepreneur, Elias Vamvakas, has scored another home run with a medical device for the diagnosis and management of dry eye disease (DED). The TearLab Osmolarity System uses a novel lab-on-a-chip approach that requires less than 50 nanoliters of tear fluid in order to measure […]

TearLab included in Feltl’s 2014 Top Idea List

TearLab included in Feltl’s 2014 Top Idea List

January 2, 2014 by · Leave a Comment 

Tweet Feltl & Co. has released its 2014 Top Idea List, which included TearLab (NASDAQ:TEAR; TSX:TLB). Analyst Ben Haynor writes that TearLab has first-mover advantage in point-of-care diagnostics for dry eye disease (DED). The TearLab Osmolarity System is a lab-on-a-chip system that provides a quantitative measure (osmolarity) of DED in less than 30 seconds. He […]

AOA goes to bat for TearLab test with private insurers

AOA goes to bat for TearLab test with private insurers

December 20, 2013 by · Leave a Comment 

http://www.youtube.com/watch?v=p24huh7sOpI&feature=c4-overview-vl&list=PL8GkKmXDug1dWbk6nDUxsQBnR-jEi1vtr’]

Tweet The Third Party Center of the American Optometric Association has worked with several state payers to establish a favorable coverage and reimbursement policy for the diagnosis of dry eye disease using the TearLab (NASDAQ:TEAR; TSX:TLB) Osmolarity Test. In late October, the center contacted the medical director of BlueCross BlueShield of Western New York (BCBSWNY) and BlueShield […]

TearLab osmolarity test in UK DED prevalence study

TearLab osmolarity test in UK DED prevalence study

December 17, 2013 by · Leave a Comment 

Tweet In collaboration with the UK’s National Health Service (NHS), four ophthalmologists are beginning a 1,000-patient multi-center study to assess the overall prevalence of dry eye disease (DED), using the TearLab (NASDAQ:TEAR; TSX:TLB) Osmolarity Test for the diagnosis of DED. Patients who suffer from a wide variety of eye complications presenting daily in NHS clinics […]

TearLab added to the MSCI US Small Cap Index

TearLab added to the MSCI US Small Cap Index

November 25, 2013 by · Leave a Comment 

Tweet As a result of the November 2013 semi-annual index review for the MSCI equity indices, TearLab (NASDAQ:TEAR; TSX:TLB) will be deleted from the MSCI US Micro Cap Index and added to the MSCI US Small Cap Index after stock market close on November 26. A summary of stock deletions and additions to the MSCI equity indices can […]

Roth starts Can-Fite BioPharma at buy

Roth starts Can-Fite BioPharma at buy

October 1, 2013 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of Can-Fite BioPharma (OTCQB:CANFY; TASE:CFBI) with a “buy” rating and $15 price target, suggesting investors own the stock ahead of two data readouts in the fourth quarter this year. Can-Fite is an Israeli company, whose ADRs recently started trading in the U.S. They closed at $5.03 on Monday. […]

TearLab Q2 gets high marks from analysts

TearLab Q2 gets high marks from analysts

August 15, 2013 by · Leave a Comment 

Tweet TearLab (NASDAQ:TEAR; TSX:TLB) received widespread support from analysts after the company’s conference call on Tuesday evening, which included a panel discussion with four eye care professionals who use the TearLab Osmolarity System in their businesses. Feltl & Co. analyst Ben Haynor, who has raised his price target to $17 from $15 and reiterated his […]

Roth ups TearLab price target to $15

Roth ups TearLab price target to $15

August 12, 2013 by · Leave a Comment 

Tweet Roth Capital Partners has raised its price target for “buy-rated” TearLab (NASDAQ:TEAR; TSX:TLB) to $15 from $9, citing the company’s better-than-expected second quarter preliminary results, common stock offering, and forecasts for an improved forward outlook. The stock closed at $12.12 on Friday. “Once again, TearLab’s second quarter orders well-surpassed our projection, reflecting a continued […]

TearLab sets public offering; announces preliminary Q2 results

TearLab sets public offering; announces preliminary Q2 results

July 22, 2013 by · Leave a Comment 

Tweet TearLab (NASDAQ:TEAR; TSX:TLB) intends to offer common shares in an underwritten public offering to raise an estimated $30-million, with an additional $4.5-million subject to an underwriters’ over-allotment option. Canaccord Genuity and Craig-Hallum Capital Group are acting as joint book-running managers for the offering, with Feltl & Co. and Roth Capital Partners acting as co-managers. […]

TearLab added to Russell 3000, Russell 2000 and Russell Global Indexes

TearLab added to Russell 3000, Russell 2000 and Russell Global Indexes

July 1, 2013 by · Leave a Comment 

Tweet TearLab (NASDAQ:TEAR; TSX:TLB) was added to the Russell 3000, Russell 2000, and Russell Global Indexes when the Russell Investment Group reconstituted its family of US indexes after stock market close on June 28. Annual reconstitution of Russell’s U.S. indexes captures the 4,000 largest U.S. stocks as of the end of May, ranking them by total […]

Next Page »

Google+